home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 07/19/23

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - Ai-Media Introduces LEXI Viewer: Revolutionizing Live Events with Cutting-Edge Captioning Solution

BROOKLYN, N.Y., July 19, 2023 (GLOBE NEWSWIRE) -- Ai-Media , the industry leader in technology-driven live captioning, transcription, and translation solutions, is delighted to unveil the ground-breaking LEXI Viewer . This innovative solution revolutionizes how event organizers captivate ...
AIM - AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates

OCALA, Fla., July 18, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a notice that the Company has learned that unknown person(s) and/or organization(s) are claiming to represent AIM ImmunoTech Europe and are...

AIM - AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today ann...

AIM - AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series

OCALA, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira...
AIM - AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research

OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its TLR-3 agonist Ampligen (rintatolimod) as a novel and potentially powerf...

AIM - AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreati

Ampligen has shown therapeutic synergies with checkpoint inhibitors, potentially increasing survival rates and efficacy Patient enrollment expected to commence before the end of 2023 OCALA, Fla., June 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ...

AIM - AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and vira...
AIM - AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of Nebraska for Phase 2 study of Ampligen® for the treatment of pancreatic cancer (AMP-270) Ongoing progress toward Phase 1 d...

AIM - AIMIA ADOPTS SHAREHOLDER RIGHTS PLAN TO PROTECT AGAINST "CREEPING" BIDS AND UNEQUAL TREATMENT OF SHAREHOLDERS

AIMIA ADOPTS SHAREHOLDER RIGHTS PLAN TO PROTECT AGAINST "CREEPING" BIDS AND UNEQUAL TREATMENT OF SHAREHOLDERS Canada NewsWire TORONTO , June 7, 2023 /CNW/ - Aimia Inc. (TSX: AIM) (" Aimia ") announces that its board of directors (the " Board ") has a...

AIM - Ai-Media to Launch AI-Powered Automatic Captioning Solution to Asian Market at BroadcastAsia

SYDNEY, Australia, June 06, 2023 (GLOBE NEWSWIRE) -- Ai-Media , the leader in technology-driven live captioning, transcription, and translation solutions, is excited to announce its presence at BroadcastAsia in Singapore, where it will unveil its ground-breaking LEXI 3.0 automatic caption...
Previous 10 Next 10